Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
ABN: 86 139 590 319
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: enquiries@ndr.org.au
Web: www.ndr.org.au

CREST-E

A Huntington's Disease Study

Aim

To assess the effects of creatine monohydrate on the progression of functional decline in Huntington's Disease as measured by the change in the Total Functional Capacity (TFC) scale over 36 months.

Phase III

Creatine Safety, Tolerability and Efficacy in Huntington's Disease

Hypothesis

Disturbed energy metabolism contributes to neurodegeneration in Huntington's Disease. Creatine increases cellular reserves of high energy phosphates, reducing cell death and improving functional capacity.

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: research@ndr.org.au

TGA Trial 2009/0572

Funding

- National Center for Complementary and Alternative Medicine (a division of the US National Institutes for Health)
- US Food and Drug Administration (Orphan Products Division)
- York Neuroscience Discovery Inc

Criteria

To be eligible for the CREST-E Study participants must:

- be 18 years or older,
- have clinical features of Huntington's disease,
- be ambulatory and not require skilled nursing care,
- be capable of providing informed consent, and
- be able to take oral drug.

Status

Now enrolling

Ethics approval

Joondalup Health Campus Human Research Ethics Committee (0912)